| All treatments | Non-biologic DMARDs | Biologic DMARDs | Etanercept | Adalimumab | Infliximab | Abatacept | Rituximab |
---|---|---|---|---|---|---|---|---|
N periods of treatment of the rheumatologic disease | 98 | 40 | 58 | 19 | 4 | 12 | 10 | 9 |
Total N infections | 93 | 16 | 77 | 13 | 3 | 34 | 23 | 4 |
N patient-years of follow-up | 194 | 98 | 96 | 33 | 1 | 30 | 17 | 12 |
N infections per patient-year, mean (SD) [95% CI] | 0.8 (1.4) [0-3.6] | 0.2 (0.5) [0-1.2] | 1.2 (1.6) [0-4.3] | 0.8 (1.4) [0-3.5] | 2.3 (2.1) [0-6.4] | 1.9 (1.6) [0-5.0] | 1.9 (1.9) [0-5.6] | 0.3 (0.7) [0-1.7] |